Gastroesophageal Junction Adenocarcinoma - Immunotherapy - PD-L1 expression

Association details:

Biomarker:	PD-L1 expression
Cancer:	Gastroesophageal Junction Adenocarcinoma
Drug Class:	Immunotherapy
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: B - Late Trials

Source:

Crit Rev Oncol Hematol

Title:

A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma

Published date:

11/18/2020

Excerpt:

PD-L1 positivity was significantly associated with survival benefit from ICIs (HR: 0.82, p 0.047), with a significant interaction between PD-L1 expression and ICI efficacy (interaction HR: 1.41, p 0.02).

DOI:

10.1016/j.critrevonc.2020.103173